Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Thomas Jefferson University
With
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
March of Dimes
This will be a longitudinal addition to an existing R21cohort enrolled in the first trimester to include a first and third trimester assessment of pharmacokinetics/pharmacodynamics (PK/PD) of aspirin and how individual factors impact aspirin PK/PD in pregnancy.
Age
13–55
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
\<16 weeks' gestational age
Singleton pregnancy
Plan to take 81mg aspirin due to high risk history (below), but not yet initiated
≥1 risk factor:
* Chronic hypertension
* Type I or II diabetes
* Previous preeclampsia
* Renal disease
* Autoimmune disease (SLE) OR
≥2 risk factor:
* Nulliparity
* IVF pregnancy
* Black race or socioeconomic disadvantaged
* BMI\>30
* Prior adverse pregnancy outcome
You may not be if
Contraindication to aspirin
Current or planned use of any other anticoagulation
Current need for dialysis
Use of aspirin therapy prior to enrollment in the current pregnancy
Thrombocytopenia (\<150)
Other known platelet disorder/thrombophilia at enrollment
